Omnipaque™ (iohexol) injection

approved since 1985, this low-osmolar iodinated contrast media is indicated for intravenous, intra-arterial, intrathecal, intraarticular, body cavity and oral use¹

Scan after Scan

Every 2 seconds, 5 patient procedures are performed using Omnipaque²

Prescribing Confidence

Omnipaque was associated with comparable rates of acute adverse events amongst LOCM in a prospective, randomized, observational study of 8,931 CT patients³

Enhancing oral procedures

Patients preferred the taste of Omnipaque over barium sulfate contrast

Promoting workflow efficiency

Omnipaque is available in a range of container sizes to suit clinical needs
ABOUT OMNIPAQUE

Omnipaque has been at least equivalent to any low-osmolar contrast media for either diagnostic efficacy or tolerability at equi-attenuating doses in head-to-head trials.11-20

Patient after patient

Omnipaque provides reliabilty and choice

• Indicated for intravenous, intra-arterial, intrathecal, intraarticular, body cavity and oral uses¹
• Approved for use in both adults and children¹
Scan after scan

Prescribing confidence with Omnipaque

Omnipaque was associated with comparable rates of acute adverse events amongst LOCM In a prospective, randomized, observational study of 8,931 CT patients³
Taste after Taste

Enhancing oral procedures

Omnipaque injection at multiple concentrations is approved for oral use in undiluted form for radiographic imaging of the GI tract.
Omnipaque injection at multiple concentrations is approved for oral use in diluted form for CT of the abdomen in conjunction with Omnipaque injection administered intravenously.
Omnipaque oral solution is a prediluted solution available in two iodine concentrations, approved for oral use for CT of the abdomen in conjunction with Omnipaque injection administered intravenously.

• 81% of adult body CT patients, who expressed a preference for positive oral contrast media, preferred Omnipaque over diatrizoate⁵
• 98% of paediatric patients undergoing abdominal CT, including patients under 5, drank the required volume of Omnipaque⁶
Bottle after Bottle

Omnipaque's +PLUSPAK packaging support departmental efficiency

• Color coded labelling to prevent administration errors
• Important information is repeated upside down so it's easier to read at any angle
• Reducing hazard and downtime with no more broken bottles and injuries from ring pulls⁷
• Reducing costs and environment impact with less storage space and lower disposal costs7-9
Scan after scan

Supporting patient throughput with Omnipaque IBP capacity

• Omnipaque IBP can be used for up to 8 hours from initial puncture. Store Omnipaque IBP at controlled room temperature, 20° to 25°C (68° to 77°F).¹
• Using Omnipaque IBP may result in lower volumes of contrast media wastage and fewer bottle spikes compared with single-dose Omnipaque injection.²¹
• Omnipaque IBP is for use only with an automated contrast injection system, contrast management system, or contrast media transfer set cleared for use with this contrast agent in this Imaging Bulk Package. See device labeling for information on devices indicated for use with this Imaging Bulk Package and techniques to help assure safe use¹

REFERENCES
  1. Omnipaque [prescribing information]. Marlborough, MA: GE HealthCare. 2023.
  2. GE HealthCare Data on File: Omnipaque Demand; 2022
  3. Gomi T et al. Are there any differences in acute adverse reactions among five low-osmolar non-ionic iodinated contrast media? Eur Radiol. 2010; 10(7):1631-5
  4. Parakh A et al. Low-keV and Low-kVp CT for Positive Oral Contrast Media in Patients with Cancer: A Randomized Clinical Trial. Radiology. 2019; 291(3): 620-29
  5. McNamara M et al. Oral Contrast Media for Body CT: Comparison of Diatrizoate Sodium and Iohexol for Patient Acceptance and Bowel Opacification. Am J Roentgenol. 2010; 195: 1137–41.
  6. Smevik B, Westvik J. Iohexol for Contrast Enhancement of Bowel in Pediatric Abdominal CT. Acta Radiologica. 1990; 31: 601–4.
  7. Marshall G. Sharps injuries among radiographers: Dangers associated with opening bottles of contrast agent. Radiography. 2008; 14:128-34
  8. Gricar J et al. The Economic and Safety Impact of Glass Versus Polymer Containers in a Radiology Department. Radiology Management. 2007: Sept/Oct 34-42
  9. Dhaliwal H et al. A life cycle assessment of packaging options for contrast media delivery: comparing polymer bottle vs. glass bottle. Int J Life Cycle Assess. 2014; 19:1965-73
  10. GE HealthCare Data on File
  11. Lamb JT. Iohexol vs. Iopamidol for Myelography. Investigative Radiology. 1985; 20(Suppl.) S37–S43.
  12. Rubin CME et al. Comparison of low-osmolar contrast media in paediatric cardiac angiography. British Journal of Radiology. 1987; 60: 133–5.
  13. Harding JR et al. A randomized, double-blind, parallel group trial of iomeprol, iohexol and iopamidol in intravenous urography. British Journal of Radiology. 1995; 68: 712–5.
  14. Faykus MH et al. Double-Blind Study of the Safety, Tolerance, and Diagnostic Efficacy of Iopromide as Compared with Iopamidol and Iohexol in Patients Requiring Aortography and Visceral Angiography. Invest Radiol. 1994; 29 (Suppl.1): S98–S101.
  15. Bischoff W. Clinical Experience with lohexol Versus lopromide in Excretory Urography. Fortschr Röntgenstr. 1989; 128: 108–10.
  16. Kaufman AJ et al. Ioversol for Intravenous Urography: A Comparison Study. Urologic Radiology. 1990; 12: 56–60.
  17. Cutcliff WB et al. A Double-Blind Comparative Study of the Safety, Tolerability, and Efficacy of Ioversol and Iohexol in Peripheral and Visceral Arteriography. Invest Radiol. 1989; 24 (Suppl.1): S56–9.
  18. LaBounty, T et al. Withi-Hospital and 30-Day Outcomes in 107,994 Patients Undergoing Invasive Coronary Angiography With Different Low-Osmolar Iodinated Contrast Media. American Journal of Cardiology. 2012
  19. McCullough PA et al. Rate of major adverse renal or cardiac events with iohexol. J Comp Eff Res 2018; 7: 331-41.
  20. Dillman JR, al-Hawary M, Ellis JH. Comparative investigation of i.v. iohexol and iopamidol: effect on renal function in low-risk outpatients undergoing CT. AJR Am J Roentgenol. 2012;198:392-397.
  21. Mattinson T, et al. Improving CT workflow and in a busy subspeciality emergency room using a novel power injector technology. In RSNA; Nov. 27- Dec. 1, 2022; Chicago, IL.


JB08209US July 2024

Have a question? We would love to hear from you.

Indications and Important Safety Information

Indications and Use – Omnipaque™ (iohexol)

Intrathecal Administration Adults: Omnipaque 180, 240, and 300 • Myelography (lumbar, thoracic, cervical, total columnar) • Computed tomography (CT) (myelography, cisternography, ventriculography) Pediatrics: Omnipaque 180 • Myelography (lumbar, thoracic, cervical, total columnar) • CT (myelography, cisternography) Intravascular Administration Adults: Omnipaque 140 • Intra-arterial digital subtraction angiography of the head, neck, abdominal, renal and peripheral vessels. Omnipaque 240 • CT head imaging • Peripheral venography (phlebography). Omnipaque 300 • Aortography including studies of the aortic arch, abdominal aorta and its branches • CT head and body imaging • Cerebral arteriography • Peripheral venography (phlebography) • Peripheral arteriography • Excretory urography. Omnipaque 350 • Angiocardiography (ventriculography, selective coronary arteriography) • Aortography, including studies of the aortic root, aortic arch, ascending aorta, abdominal aorta and its branches • CT head and body imaging • Intravenous digital subtraction angiography of the head, neck, abdominal, renal and peripheral vessels • Peripheral arteriography • Excretory urography. Pediatrics: Omnipaque 240 • CT head and body imaging. Omnipaque 300 • Angiocardiography (ventriculography) • Excretory urography • CT head and body imaging. Omnipaque 350 • Angiocardiography (ventriculography, pulmonary arteriography, venography, and studies of the collateral arteries) • Aortography, including the aortic root, aortic arch, ascending and descending aorta. Oral or Rectal Administration Adults: Omnipaque 350 • Oral radiographic examination of the gastrointestinal tract. Pediatrics: Omnipaque 180, 240, and 300 • Oral and rectal radiographic examination of the gastrointestinal tract. Oral administration in conjunction with intravenous administration: Diluted Omnipaque Injection Adults: Omnipaque 240, 300, and 350 diluted and administered orally in conjunction with Omnipaque 300 administered intravenously • CT of the abdomen. Pediatrics: Omnipaque 240, 300, and 350 diluted and administered orally in conjunction with Omnipaque 240 or Omnipaque 300 administered intravenously • CT of the abdomen. Omnipaque Oral Solution Adults: Omnipaque Oral Solutions 9 and 12 administered orally in conjunction with Omnipaque 300 administered intravenously • CT of the abdomen. Pediatrics: Omnipaque Oral Solutions 9 and 12 administered orally in conjunction with Omnipaque 240 or Omnipaque 300 administered intravenously • CT of the abdomen. Intra-articular Administration Adults: Omnipaque 240, 300, and 350 • Arthrography. Body Cavity Administration Adults: Omnipaque 240 • Endoscopic retrograde pancreatography (ERP) and endoscopic retrograde cholangiopancreatography (ERCP) • Herniography • Hysterosalpingography. Omnipaque 300 • Hysterosalpingography. Pediatrics: Omnipaque 240, 300, and 350 diluted • Voiding cystourethrography (VCU).

IMPORTANT SAFETY INFORMATION ABOUT OMNIPAQUE™ (iohexol)

WARNING: RISKS WITH INADVERTENT INTRATHECAL ADMINISTRATION OF

Omnipaque Injections 140 and 350 mgI/mL


Inadvertent intrathecal administration may cause death, convulsions/seizures, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, rhabdomyolysis, hyperthermia, and brain edema.


CONTRAINDICATIONS:

• OMNIPAQUE 140 and OMNIPAQUE 350 are contraindicated for intrathecal use.
• OMNIPAQUE Oral Solutions 9 and 12 are contraindicated for parenteral administration.
• OMNIPAQUE body cavity 240 and 300 for hysterosalpingography is contraindicated during pregnancy (or suspected pregnancy), menstruation (or when menstruation is imminent), within 6 months after termination of pregnancy, within 30 days after conization or curettage, when signs of infection are present in any portion of the genital tract, including the external genitalia, and when reproductive tract neoplasia is known or suspected.

WARNINGS AND PRECAUTIONS:

• Hypersensitivity Reactions: Life-threatening or fatal hypersensitivity reactions, including anaphylaxis can occur. Most severe reactions develop within 3 minutes of injection start, but reactions can occur hours later. Increased risk exists in patients with previous reaction to contrast agents and known allergies (ie, bronchial asthma, drug, food allergies) or other hypersensitivities. Always have emergency resuscitation equipment and trained personnel available. Monitor all patients for hypersensitivity reactions.
• Contrast-Induced Acute Kidney Injury: Acute injury, including renal failure, may occur after parenteral administration. Risk factors include renal impairment, dehydration, diabetes mellitus, congestive heart failure, advanced vascular disease, elderly age, concomitant nephrotoxic or diuretic medications, multiple myeloma/paraproteinaceous diseases, and repetitive and/or large doses of an iodinated contrast agent. Minimize dose and maintain adequate hydration.
• Cardiovascular Adverse Reactions: Life-threatening or fatal cardiovascular reactions, including hypotension, shock, and cardiac arrest have occurred with the parenteral administration. Most deaths occur during injection or 5-10 minutes later, with cardiovascular disease as the main aggravating factor. Cardiac decompensation, serious arrhythmias, and myocardial ischemia or infarction can occur during coronary arteriography and ventriculography. Monitor all patients for severe cardiovascular reactions.
• Thromboembolic Events: Angiocardiography - Serious, rarely fatal, events causing myocardial infarction and stroke can occur during a procedure as increased thrombosis and activation of the complement system occurs. Risk factors include procedure length, catheter/syringe material, underlying disease, concomitant medications. Use meticulous angiographic techniques, minimize length of procedure. Avoid blood remaining in contact with syringes containing iodinated contrast agents. Avoid angiocardiography in patients with homocystinuria.
• Extravasation and Injection-Site Reactions: Extravasation during intravascular injection may cause tissue necrosis and/or compartment syndrome, particularly in patients with severe arterial or venous disease. Ensure intravascular placement of catheters, monitor patients for extravasation, and advise patients to seek medical care for progression of symptoms.
• Thyroid Storm in Patients with Hyperthyroidism: Thyroid storm has occurred after the intravascular use of iodinated contrast agents in patients with hyperthyroidism, or with an autonomously functioning thyroid nodule.
• Thyroid Dysfunction in Pediatric Patients 0 to 3 Years of Age: Thyroid dysfunction characterized by hypothyroidism or transient thyroid suppression has been reported after both single exposure and multiple exposures to iodinated contrast media. Among patients 0 to 3 years of age exposed to iodinated contrast media, thyroid dysfunction has been reported in 1% to 15% depending on the age of the patient and the dose of the iodinated contrast agent. Monitor these patients for thyroid function abnormalities and treat as clinically needed.
• Hypertensive Crisis in Patients with Pheochromocytoma: Hypertensive crisis has occurred after the use of iodinated contrast agents in patients with pheochromocytoma. Inject the minimum amount of contrast necessary, assess the blood pressure throughout the procedure, and have measures for treatment of a hypertensive crisis readily available.
• Sickle Cell Crisis in Patients with Sickle Cell Disease: Iodinated contrast agents, when administered intravascularly, may promote sickling in individuals who are homozygous for sickle cell disease. Hydrate patients prior to and following OMNIPAQUE administration and use OMNIPAQUE only if the necessary imaging information cannot be obtained with alternative imaging modalities.
• Severe Cutaneous Adverse Reactions (SCAR): SCAR may develop from 1 hour to several weeks after IV contrast administration. These include Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN), acute generalized exanthematous pustulosis (AGEP), and drug reaction with eosinophilia and systemic symptoms (DRESS). Reaction severity may increase, and time to onset may decrease, with repeat administration of contrast agents; prophylactic medications may not prevent or mitigate SCARs. Avoid administering to patients with a history of a SCAR to OMNIPAQUE.

USE IN SPECIFIC POPULATIONS:
Please consult the full Prescribing Information before using OMNIPAQUE in patients who are: pregnant or may be pregnant, lactating, pediatric or geriatric.

ADVERSE REACTIONS:
• Intrathecal: Headaches, pain including backache, neckache, stiffness and neuralgia, nausea, vomiting, dizziness.
• Intravascular: Pain, vision abnormalities, (including blurred vision and photomas), headache, taste perversion, arrhythmias including premature ventricular contractions (PVCs) and premature atrial contractions (PACs), angina/chest pain, nausea.
• Oral:Diarrhea, nausea, vomiting, abdominal pain, flatulence, headache.
• Body cavity: Pain, swelling, heat sensation.
• Postmarketing adverse events seen include: Hypersensitivity and manifestations such as rash, pruritus, urticaria and dyspnea, chest pain, swelling.

DRUG-DRUG INTERACTIONS:

• Metformin: Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function in patients with renal impairment. Stop metformin at the time of, or prior to, injection of OMNIPAQUE. Reevaluate eGFR 48 hours after imaging procedure. Reinstitute metformin only after renal function is stable.
• Radioactive Iodine: Administration of iodinated contrast agents may interfere with thyroid uptake of radioactive iodine (I-131 and I-123) and decrease therapeutic and diagnostic efficacy in patients with carcinoma of the thyroid.
• Beta-Adrenergic Blocking Agents: Use of beta-adrenergic blocking agents lowers the threshold for, and increases the severity of, contrast reactions and reduces the responsiveness of treatment of hypersensitivity reactions with epinephrine. Use caution when administering OMNIPAQUE to patients taking beta-blockers.
• Drugs That Lower Seizure Threshold: Drugs that lower seizure threshold, especially phenothiazine derivatives, including those used for their antihistaminic or antinauseant properties, are not recommended for use with intrathecal administration of OMNIPAQUE.
• Central Nervous System (CNS) Active Drugs: Drugs like monoamine oxidase (MAO) inhibitors, tricyclic antidepressants, CNS stimulants, psychoactive drugs described as analeptics, major tranquilizers, or antipsychotic drugs should be discontinued at least 48 hours before myelography, should not be used for the control of nausea or vomiting during or after myelography, and should not be resumed for at least 24 hours post-procedure. In nonelective procedures in patients on these drugs, consider prophylactic use of anticonvulsants.

Prior to Omnipaque administration, please read the full Prescribing Information including Boxed Warning for Omnipaque. Also read the full Prescribing Information for Omnipaque Imaging Bulk Package and Omnipaque Pharmacy Bulk Package

To report SUSPECTED ADVERSE REACTIONS, contact GE HealthCare at 800 654 0118 (option 2), or the FDA at 800 FDA 1088 or www.fda.gov/medwatch.

JB08209US July 2024